Gara Jalqabaatti › Obesity › Oklahoma
Qorannoo klinikaalii Obesity Oklahoma keessatti
Qorannoo 21 Obesity f Oklahoma keessatti hirmaatuu jiru.
Magaalota Oklahoma keessatti
Takkalaa qorannoo (Ingiliffa)
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Alliance for Multispecialty Research - Norman, Norman
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 99 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT07684235A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Children's Physicians OU, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 8 hanga 18 · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT07253285Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- Lynn Health Science Institute, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT07837973AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Lynn Institute of Norman, Norman
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT07720271A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- University of Oklahoma Health Sciences Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 6 hanga 17 · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06672549Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Central States Research, Tulsa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07353931A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- South Oklahoma Heart Research, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 99 · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Lynn Institute of Norman, Norman
- Lynn Health Science Institute, Oklahoma City
- Essential Medical Research, Tulsa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Alliance for Multispecialty Research, LLC, Norman
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT06897475A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Delricht Research of Tulsa Clinical Trials, Tulsa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Moore
- ACCOMPLISH-2 Research Site, Tulsa
- ACCOMPLISH-2 Research Site, Yukon
Namoota walitti qabaa jiraSadarkaa 3Hojjettoota fayyaa simatamoo
Umuriin 18 hanga 79 · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT07654374Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Chickasha
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT07284901Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Chickasha
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT07284875Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Kailera Clinical Site, Norman
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Ful-2026 · NCT07284979Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Epic Medical Research - Oklahoma, Chickasha
- Lynn Health Science Institute, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 99 · Saalaa hunda · Haaromfame 27-Hag-2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Tulsa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT07784725Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Moore
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 79 · Saalaa hunda · Haaromfame 10-Hag-2026 · NCT07654361A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
- AMR Norman, Norman
- Lynn Health Science Institute, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 22-Ado-2026 · NCT07477704Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- University of Oklahoma, Norman
Namoota walitti qabaa jira
Umuriin 18 hanga 45 · Dubartoota · Haaromfame 24-Wax-2026 · NCT05124808Uterine Preservation Via Lifestyle Transformation
- University of Oklahoma, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 20-Ama-2026 · NCT05903131Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.